Key result
Bupropion demonstrated a wider cardiovascular safety margin than nortriptyline, which caused significant heart rate increases and symptomatic orthostatic hypotension.
Why the study?
Does bupropion have a better cardiovascular safety profile compared to nortriptyline in adult outpatients with major depression?
RCT (n=115)
Double-blind
randomized
Does bupropion have a better cardiovascular safety profile compared to nortriptyline in adult outpatients with major depression?
Bupropion demonstrates a wider cardiovascular safety margin compared to nortriptyline in depressed outpatients, avoiding the significant heart rate increases, symptomatic orthostatic hypotension, and conduction slowing seen with nortriptyline.
Answers are grounded in this paper and cite their sources.
Nortriptyline warrants heart rate monitoring in depressed patients; extends RCT evidence of differential cardiovascular effects versus bupropion.
The cardiovascular effects of bupropion hydrochloride and nortriptyline were compared in a double-blind, randomized, 6-week trial in adult outpatients with major depression. After a 1-week placebo phase, 58 patients were randomized to treatment with bupropion (225-450 mg/day) and 57 to nortriptyline (75-150 mg/day). Nortriptyline-treated patients had statistically significant heart rate increases at each assessment as determined by RR intervals on electrocardiogram (14.5-18 bpm). Bupropion-treated patients had small but statistically significant increases in supine diastolic blood pressure of 5.6 mm Hg on day 7 and 7.5 mm Hg on day 28. A few patients in each treatment group had orthostatic changes, but only nortriptyline-treated patients had symptomatic orthostatic hypotension. A slowing of cardiac conduction and possibly of rate-corrected repolarization occurred in patients treated with nortriptyline that did not occur in patients treated with bupropion. Compared to nortriptyline, bupropion appears to have a wider safety margin with regard to cardiovascular effects. This may be particularly true in the elderly, in patients with preexisting cardiovascular disease, or in overdose.
No takes yet. Share an insight, caveat, or question.
Kiev et al. (1994) conducted an RCT in Major depression (n=115). Bupropion vs. Nortriptyline (75-150 mg/day) was evaluated on Cardiovascular effects (heart rate, blood pressure, orthostatic changes, cardiac conduction). Bupropion demonstrated a wider cardiovascular safety margin than nortriptyline, which caused significant heart rate increases and symptomatic orthostatic hypotension.
Synapse has enriched 10 related papers. Consider them for comparative context: